Prime medicine announces strategic restructuring to focus on opportunities in large genetic liver diseases, cystic fibrosis, and partnered programs alongside ceo leadership transition

-- initial positive data from phase 1/2 clinical trial of pm359 in cgd provide clinical proof-of-concept for prime editing as a transformative gene editing technology -- -- on-track to file ind and/or cta for wilson's disease and aatd programs in 1h 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 --
PRME Ratings Summary
PRME Quant Ranking